Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
Jiawen Cui, Yao Li, Yang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116203-116203
Open Access | Times Cited: 36

Showing 26-50 of 36 citing articles:

Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management
Salem Baldi, Mohammed Alnaggar, Maged AL-Mogahed, et al.
The EPMA Journal (2025)
Closed Access
Cancer Cell Secreted Legumain Promotes Gastric Cancer Resistance to Anti-PD-1 Immunotherapy by Enhancing Macrophage M2 Polarization
Xu Pei, Shilong Zhang, Bai‐Quan Qiu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 951-951
Open Access | Times Cited: 3
PTBP3 Mediates IL‐18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer
Cheng Zhao, Yu Zhao, Yuhan Zhang, et al.
Advanced Science (2024) Vol. 11, Iss. 38
Open Access | Times Cited: 3
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment
Lingrong Hu, Chengliang Sun, Kai Yuan, et al.
Drug Discovery Today (2024), pp. 104181-104181
Closed Access | Times Cited: 2
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Baofa Yu, Shengwen Shao, Wenxue Ma
Cancer Letters (2024), pp. 217350-217350
Open Access | Times Cited: 2
Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors
Nevena Ilieva, Mina Pencheva, Hristo Hadzhiev, et al.
Diagnostics (2024) Vol. 14, Iss. 23, pp. 2672-2672
Open Access | Times Cited: 1
Disulfide bond-rich Nano-Silica for High-Efficiency cancer immunotherapy using synergistic endoplasmic reticulum stress cooperated mitochondrial dysfunction
Jialin Ni, Hailong Tian, Siyuan Qin, et al.
Chemical Engineering Journal (2024) Vol. 498, pp. 154877-154877
Closed Access | Times Cited: 1
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
Yogesh Godiyal, Drishti Maheshwari, Hiroaki Taniguchi, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Holliday junction recognition protein (HJURP) could reflect the clinical outcomes of lung adenocarcinoma patients, and impact the choice of precision therapy
Xixi Gao, Yingqing Zhang, Ming Zhang, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access
mRNA-based cancer vaccines: A novel approach to melanoma treatment
Pranav Kumar Prabhakar, Tarun Kumar Upadhyay, Sanjeev Kumar Sahu
Advances in immunology (2024)
Closed Access
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Abdulaziz M. Eshaq, Thomas W. Flanagan, Anass Abbad, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 88-88
Open Access
Machine learning-based pan-cancer study of classification and mechanism of BRAF inhibitor resistance
Yuhang Zhao, Kai Yang, Yujun Chen, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 12, pp. 6645-6660
Open Access
Previous Page - Page 2

Scroll to top